Biotechnology Hypertension Trials
A fast-moving biotechnology sponsor initiated a series of complex Phase II and Phase III clinical trials targeting uncontrolled and resistant hypertension.
These global studies involved many investigative sites and patients spread across numerous complex regulatory environments.